Congress-AAIC
Congress-AAIC-Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Renal Association (ERA) 2025

Congress Details

calanderJune 4-7, 2025

locationVienna, Austria

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Image
Oral

Congress Materials

Image
icon Presentation Type
Presentation
Image
location icon Location
Vienna, Austria
Image
icon Title
Long-Term Efficacy and Safety in the 60-Month, Phase 3 ILLUMINATE-B Trial of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1